Search other companies ESG researched by sustainAX here
Dropdown Menu with Searchable Options

Integrum AB – ESG risk research and ESG rating

We at sustainAX have ESG risk researched and ESG risk rated Integrum AB and our clients can access the reseach on their Bloomberg terminals.

Integrum AB is in the materiality based sector of PHARMA, BIOTECH AND LIFE SCIENCES.

Our ESG risk research of Integrum AB

Our approach to ESG research is fundamental, that means that we have studied all relevant publications by Integrum AB and combined this with fundamental understanding of ESG challenges and risks of different activities and for the PHARMA, BIOTECH AND LIFE SCIENCES sector. This makes us well placed to estimate the ESG risks of Integrum AB. We have published a 33 pages ESG research report on Integrum AB with a conclusion highlighting the most important residual risks, a section suggesting how it should be integrated in investment decisions and a list of all the questions we think should be asked to Integrum AB.

More about our ESG risk research here:


20-40 of 100

High risk

Where 100 is the lowest ESG risk and 0 is the highest risk.

*The ESG, E, S and G risk rating ranges indicate to what degree Integrum AB has addressed and mitigated their material ESG risks according to the sustainAX materiality matrix. sustainAX’ clients have access to the exact ESG risk rating. 

**The weight in the aggregated ESG rating

Environmental RISK RATING* and WEIGHT** for Integrum AB:
0-20 of 100 Very High risk
Social RISK RATING* and WEIGHT** for Integrum AB:
40-60 of 100 – Middle risk
Governance RISK RATING* and WEIGHT** for Integrum AB:
40-60 of 100 – Middle risk
About the company:

Integrum is a medical technology company listed on Nasdaq First North in Stockholm that develops and markets systems for skeletal anchored amputation prostheses. With operations carried out in fourteen countries and having been active in the market for over 20 years, the company has a world-leading position in the field. Integrum's unique OPRA TM Implant System helps improve the quality of life for amputees worldwide. The positive effects associated with bone-anchored prostheses have been demonstrated in several clinical studies. In addition, Integrum conducts groundbreaking research in related technology areas and has, among other things, developed techniques for mind-controlled prostheses and treatment of phantom limb pain.

Are you interested in the ESG research and ESG rating?

If you are interested in the ESG risk research and ESG risk rating of Integrum AB, contact us at sustainAX!

© Copyright SustainAX AB and, 2024. Please note that by accessing and using the SustainAX AB website, you are consenting to comply with our Terms of Use and acknowledging the acceptance of any inherent risks. The content provided on this site is available for your non-commercial, non-competitive use, specifically for the purposes of understanding companies’ environmental, social, and governance (ESG) risks. Should you wish to employ our information within a professional capacity, it is incumbent upon you to secure the appropriate licensing rights from us. Be aware that any form of unauthorised data extraction or the systematic electronic harvesting of our content is expressly forbidden.

Generated by MPG